In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor.
Zhou J, Khng J, Jasinghe VJ, Bi C, Neo CH, Pan M, Poon LF, Xie Z, Yu H, Yeoh AE, Lu Y, Glaser KB, Albert DH, Davidsen SK, Chen CS.
Zhou J, et al. Among authors: jasinghe vj.
Leuk Res. 2008 Jul;32(7):1091-100. doi: 10.1016/j.leukres.2007.11.025. Epub 2007 Dec 26.
Leuk Res. 2008.
PMID: 18160102